The digital pathologist & computerized image analysis of histopathology
Over the last decade, the nature of diagnostic healthcare has changed rapidly owing to an explosion in the availability of patient data for disease diagnosis. Traditional methods of ana lysis of cancer samples were limited to a few variables, usually stage, grade and the measure ment of a few clinical markers, such as estrogen receptor, progesterone receptor, HER2 for breast cancer and prostatespecific antigen for prostate cancer (CaP). The pathologist was trained to synthesize this information into a diagnosis that would help the clinician determine the best course of therapy. These data were also used to try to understand the molecular basis of cancer with the goal of improving therapy.
With the recent advent and cost-effective ness of wholeslide digital scanners, tissue histo pathology slides can now be digitized and stored in digital image form. With the availability and ana lysis of a much larger set of variables combined with sophisticated imaging and ana lysis techniques, the traditional paradigm of a patho logist and a microscopy could rapidly be replaced with a digital pathologist relying on a large flat screen panel to view and rapidly analyze digitized tissue sections.
Computer-aided diagnosis of histopathology
Over the past decade, dramatic increases in com putational power and improvement in image ana lysis algorithms have allowed the develop ment of powerful computerassisted analytical approaches to biomedical data. Just as with digi tal radiology over two decades ago, digitized tis sue histopathology has now become amenable to the application of computerized image ana lysis and machinelearning techniques for accurate diagnosis. In the context of CaP, for example, of the approximately 1 million biopsies performed in the USA every year, only 20% are found to be positive for cancer. This implies that pathologists are spending a large fraction of their time look ing at benign tissue, which in most cases is easily distinguishable from cancer [1, 2] . This represents a huge waste of time and resources that might be better spent analyzing patients who actually have CaP, or to focus on the cases where the disease is difficult to identify/classify or presents with nonstandard features. Consequently, several researchers have begun to develop computer aided diagnosis methods by applying image processing and computer vision techniques to try and identify spatial extent and location of diseases such as breast cancer [3] [4] [5] [6] [7] [8] [9] , CaP [10] [11] [12] [13] [14] [15] [16] [17] , neuroblastomas and meningiomas [18] [19] [20] [21] on digitized tissue sections.
One of the principal challenges in ana lysis of digital histopathology data is the enormous density of data that the algorithms have to con tend with, compared with radiological and other imaging modalities. For instance, the largest radiological datasets obtained on a routine basis are highresolution chest CT scans comprising approximately 512 × 512 × 512 spatial elements or approximately 134 million voxels. A single core of prostate biopsy tissue digitized at 40× resolution is approximately 15,000 × 15,000 ele ments or approximately 225 million pixels. To put this in context, a single prostate biopsy pro cedure can comprise anywhere between 12 and 20 biopsy samples or approximately 2.5-4 bil lion pixels of data generated per patient study. Thus, unlike computeraided detection (CAD) algorithms previously proposed for radiology, histopathology CAD algorithms are typically constructed within a multiresolution frame work [22] in order for them to be rapid, efficient and accurate. 
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Computer-aided prognosis
A second important role of computerized image ana lysis of digital pathology is to identify prog nostic markers and to predict disease outcome and survival. For instance, in both breast cancer [23] [24] [25] and CaP [26] [27] [28] , cancer grade is known to be highly correlated to patient outcome and longterm survival. One of the issues with grade determination by a pathologist is the high degree of inter and intraobserver variability [25, [29] [30] [31] [32] . Since pathologist grade is reflected in tissue architecture and nuclear arrangement, graphbased [4, 5, 7, 33, 34] It is conceivable that these imagebased pre dictors may in the future become powerful and accurate enough to be able to rival more expen sive molecular prognostic assays in predicting disease outcome. For instance, for estrogen receptorpositive breast cancers, our group has been developing an imagebased risk score pre dictor that on a small cohort of data appears to perform as well as a commercial molecular gene expression assay called Oncotype DX ® [5, 16] in predicting patient outcome.
Computer-aided theragnosis
It has always been accepted that cancer is a com plex disease that we do not yet fully understand. In the clinic, the same treatment applied to two patients with diseases that look very similar have vastly different outcomes. A part of this difference is undoubtedly patient specific, but a part must also be a result of our limited under standing of the relationship between disease progression and clinical presentation. There is a consensus among clinicians and researchers that a more detailed approach, using computer ized imaging techniques to better understand tumor morpho logy, combined with the clas sification of diseases into more meaningful molecular subtypes, will lead to better patient care and more effective therapeutics. The vari ables that can be used in such an ana lysis are the molecular features of a tumor (as measured by geneexpression profiling or realtime PCR and FISH), results from the imaging of the tumor cellular architecture and microenvironment (as captured in histological imaging), the tumor 3D tissue architecture and vascularization (as measured by dynamic contrastenhanced MRI) and its metabolic features (as seen by metabolic or functional imaging modalities e.g., magnetic resonance spectroscopy or PET) [35] .
While digital pathology offers very inter esting, highly dense data, one of the exciting challenges in the future will be in the area of multimodal data fusion for making therapy recom mendations (theragnosis), especially as it pertains to personalized medicine. For instance, our group [36] has been exploring the correlation and integration of protein expression and histo logical image measurements to develop a com bined classifier to predict which CaP patients will have disease recurrence following therapy.
Role of the pathologist in the digital age
While image ana lysis methods for digital patho logy are rapidly finding application in the clinic, both imaging, computer scientists and patho logists alike need to appreciate that the primary purpose of these tools is to complement the role of the pathologist. They will not in the short or medium term be able to replace the vast domain of expertise that a pathologist brings to the table; a lesson that we can appreciate from radiology where the availability of commercial CAD sys tems over the last two decades has not in any way diminished the role of the radiologist.
"We are living in an exciting time when disease diagnostics and treatment are becoming more accurate and patient specific. Computerized imaging methods are beginning to assist … in making an accurate diagnosis of disease…"
The vast majority of histopathology image ana lysis researchers are computer vision researchers. As such, it is important to main tain a constant collaboration with clinical and research pathologists throughout the research process. There are unique challenges to ana lysis of histopathology imagery, particularly in the performances required for eventual use of the technique in a clinical setting. It is the patholo gist who can best provide the feedback on the performance of the system, as well as suggest ing new avenues of research that would provide beneficial information to the pathologist com munity. Additionally, it is the pathologist that is best equipped to interpret the ana lysis results in light of underlying biological mechanisms which, in turn, may lead to new research ideas.
Looking to the future
We are living in an exciting time when disease diagnostics and treatment are becoming more accurate and patient specific. Computerized imaging methods are beginning to assist the pathologist and radiologist in making an accu rate diagnosis of disease and identify mor phological features correlated with prognosis. Molecular profiling of disease promises to help the clinician understand the underlying bio logy of the disease and suggest new and more effective therapeutics. We stand at the thresh old of an era when predictive, preventive and personalized medicine will transform medicine by decreasing morbidity in cancer. We believe this transformation will be driven by the inte gration of multiscale heterogeneous data [9, 36] .
The goal of our research and the research of many other scientists is aimed at a future when disease diagnostics will involve the quantitative integration of multiple sources of diagnostic data, including genomic, imaging, proteomic and metabolic data acquired across multiple scales/resolutions that can distinguish between individuals or between subtle variations of the same disease to guide therapy. Quantitative crossmodal data integration will also allow disease prognostics, enabling physicians to pre dict susceptibility to a specific disease as well as disease outcome and survival. Finally, the ana lysis will provide theragnostics; the ability to predict how an individual will react to various treatments. Such a theragnostic profile would be a synthesis of various biomarkers and imag ing tests from different levels of the biological hierarchy. It would be used as the 'signature' of an individual patient, useful in predicting her/ his response to drug treatment. A collection of these profiles, followed up over time, would provide insights into the disease process and be useful for improvements in developing future treatment options. 
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